12/28/2015
`
`FiercePharma
`
`Why is Novartis' Copaxone copy lagging? It's all about coverage, analyst explains - FiercePharma
`
`Select another site Advertise Contact
`
`SEARCH
`
`Free Daily Pharma Industry Newsletter Every business day, FiercePharma updates pharmaceutical executives on the latest Pharma industry news
`and deals. Stay up to date on:
`Pharma Company News ∣ Generic Drug Companies ∣ Pharmaceutical Marketing & Sales ∣ FDA Regulations & Warnings ∣ Phase IV Clinical Trials
`Click here to see a sample.
`
`We never sell or give away your contact information. Our readers' trust comes first.
`
`EMAIL ADDRESS
`
`NEWS TOPICS ANALYSIS FEATURES LIBRARY EVENTS JOBS MARKETPLACE
`
`Why is Novartis' Copaxone copy lagging? It's all
`about coverage, analyst explains
`September 11, 2015 | By Carly Helfand
`
`Typically, the first generics for
`blockbuster meds get off to a running
`start. Not so with Novartis' ($NVS)
`generic of Teva's ($TEVA) multiple
`sclerosis standout Copaxone, though
`and Bernstein analyst Ronny Gal thinks
`he can explain why.
`
`The Swiss pharma giant's knockoff, dubbed Glatopa, right now has market share
`of only about 20%as opposed to the roughly 50% some industrywatchers say
`it's capable of snagging. And that could be because coverage of the copy is
`"considerably behind that of Copaxone," he wrote in a Friday note to clients.
`
`Copaxone reaches the "best available coverage" tier for 59% of covered lives,
`he pointed out, while Glatopa can only boast that level for 31%. Many payers
`have kept Teva's original as either preferred or equally accessible thanks to
`discounting, he noted, and on top of that, Glatopalikely thanks to its high price
`is treated by many plans as a branded product.
`
`SHARE
`
`Tweet
`
`88
`
`Share
`
`34
`
`Like
`
`0
`
`TOOLS
`
`[Webinar]Improving Commercial Content Compliance &
`Productivity: Results from New Industry Survey
`
`Comment
`
`DATE: JANUARY 21ST | 12PM ET / 9AM PT
`DISCOVER NEW TRENDS AND STRATEGIES TO IMPROVE COMPLIANCE AND
`MARKETING PRODUCTIVITY. SEE HOW YOUR ORGANIZATION COMPARES. REGISTER NOW!
`
`Print
`
`Sign up for our FREE newsletter for more news like this sent to your inbox!
`
`FOLLOW US
`
`J O I N 1 5 0 , 0 0 0 + I N S I D E R S
`SIGN UP FOR OUR
`NEWSLETTER
`
`FiercePharma is the pharma industry's daily monitor,
`with a special focus on pharmaceutical company news
`and the market development of FDA approved
`products. Join thousands of pharma industry leaders
`who get FiercePharma via daily email. Sign up today!
`
`EMAIL ADDRESS
`
`POPULAR STORIES
`
`MOST READ MOST SHARED
`
`The biosimilars are coming. But how long will it be
`till they can make their mark?
`Think we've seen the last of pharma's M&A tidal
`wave? Think again
`What's the calendar bringing biopharma next year?
`Our top 5 ideas
`Brace yourselves: The drug pricing brouhaha isn't
`dying down
`Shire inches closer to Baxalta buy with cash
`sweetened bid
`
`THE LIBRARY: WEBINAR
`Optimizing Your Clinical Supply Chain Strategy
`for AsiaPacific Studies
`
`| THURSDAY, JANUARY 28, 2016 | 10AM
`ET / 7AM PT | PRESENTED BY:
`CATALENT
`
`Contact
`Author
`
`Reprint
`
`In this webinar we will explore how to leverage
`the major clinical supply centers of China,
`Singapore and Japan to support clinical trials
`within the AsiaPacific region for both local and
`global study sponsors. We will explore clinical
`packaging, logistics and import/export
`Novartis' Sandoz unit, though, appears to be taking that tack deliberately. It "can
`considerations that should be taken into
`always lower its price and capture share," Gal noted, but right now, it "appears to
`account when developing a clinical supply
`be interested in building share cautiously in order to protect market price." The
`strategy and why there is no substitute for on
`http://www.fiercepharma.com/story/why-novartis-copaxone-copy-lagging-its-all-about-coverage-analyst-explains/2015-09-11
`
`"It appears that the lower penetration is, for the most part, factual and simply
`reflects current formulary status coverage," Gal wrote. Teva is offering more
`discount to payers, and those payers are preferring its brand over equally or
`slightly more expensive Glatopa."
`
`1/3
`
`MYLAN PHARMS. INC. EXHIBIT 1105 PAGE 1
`
`
`
`FiercePharma
`
`Why is Novartis' Copaxone copy lagging? It's all about coverage, analyst explains - FiercePharma
`
`Select another site Advertise Contact
`
`SEARCH
`
`Free Daily Pharma Industry Newsletter Every business day, FiercePharma updates pharmaceutical executives on the latest Pharma industry news
`and deals. Stay up to date on:
`Pharma Company News ∣ Generic Drug Companies ∣ Pharmaceutical Marketing & Sales ∣ FDA Regulations & Warnings ∣ Phase IV Clinical Trials
`Click here to see a sample.
`
`We never sell or give away your contact information. Our readers' trust comes first.
`
`EMAIL ADDRESS
`
`NEWS TOPICS ANALYSIS FEATURES LIBRARY EVENTS JOBS MARKETPLACE
`
`Why is Novartis' Copaxone copy lagging? It's all
`about coverage, analyst explains
`September 11, 2015 | By Carly Helfand
`
`Typically, the first generics for
`blockbuster meds get off to a running
`start. Not so with Novartis' ($NVS)
`generic of Teva's ($TEVA) multiple
`sclerosis standout Copaxone, though
`and Bernstein analyst Ronny Gal thinks
`he can explain why.
`
`The Swiss pharma giant's knockoff, dubbed Glatopa, right now has market share
`of only about 20%as opposed to the roughly 50% some industrywatchers say
`it's capable of snagging. And that could be because coverage of the copy is
`"considerably behind that of Copaxone," he wrote in a Friday note to clients.
`
`Copaxone reaches the "best available coverage" tier for 59% of covered lives,
`he pointed out, while Glatopa can only boast that level for 31%. Many payers
`have kept Teva's original as either preferred or equally accessible thanks to
`discounting, he noted, and on top of that, Glatopalikely thanks to its high price
`is treated by many plans as a branded product.
`
`SHARE
`
`Tweet
`
`88
`
`Share
`
`34
`
`Like
`
`0
`
`TOOLS
`
`[Webinar]Improving Commercial Content Compliance &
`Productivity: Results from New Industry Survey
`
`Comment
`
`DATE: JANUARY 21ST | 12PM ET / 9AM PT
`DISCOVER NEW TRENDS AND STRATEGIES TO IMPROVE COMPLIANCE AND
`MARKETING PRODUCTIVITY. SEE HOW YOUR ORGANIZATION COMPARES. REGISTER NOW!
`
`
`Sign up for our FREE newsletter for more news like this sent to your inbox!
`
`FOLLOW US
`
`J O I N 1 5 0 , 0 0 0 + I N S I D E R S
`SIGN UP FOR OUR
`NEWSLETTER
`
`FiercePharma is the pharma industry's daily monitor,
`with a special focus on pharmaceutical company news
`and the market development of FDA approved
`products. Join thousands of pharma industry leaders
`who get FiercePharma via daily email. Sign up today!
`
`EMAIL ADDRESS
`
`POPULAR STORIES
`
`MOST READ MOST SHARED
`
`The biosimilars are coming. But how long will it be
`till they can make their mark?
`Think we've seen the last of pharma's M&A tidal
`wave? Think again
`What's the calendar bringing biopharma next year?
`Our top 5 ideas
`Brace yourselves: The drug pricing brouhaha isn't
`dying down
`Shire inches closer to Baxalta buy with cash
`sweetened bid
`
`THE LIBRARY: WEBINAR
`Optimizing Your Clinical Supply Chain Strategy
`for AsiaPacific Studies
`
`| THURSDAY, JANUARY 28, 2016 | 10AM
`ET / 7AM PT | PRESENTED BY:
`CATALENT
`
`Contact
`Author
`
`Reprint
`
`In this webinar we will explore how to leverage
`the major clinical supply centers of China,
`Singapore and Japan to support clinical trials
`within the AsiaPacific region for both local and
`global study sponsors. We will explore clinical
`packaging, logistics and import/export
`Novartis' Sandoz unit, though, appears to be taking that tack deliberately. It "can
`considerations that should be taken into
`always lower its price and capture share," Gal noted, but right now, it "appears to
`account when developing a clinical supply
`be interested in building share cautiously in order to protect market price." The
`strategy and why there is no substitute for on
`http://www.fiercepharma.com/story/why-novartis-copaxone-copy-lagging-its-all-about-coverage-analyst-explains/2015-09-11
`
`"It appears that the lower penetration is, for the most part, factual and simply
`reflects current formulary status coverage," Gal wrote. Teva is offering more
`discount to payers, and those payers are preferring its brand over equally or
`slightly more expensive Glatopa."
`
`1/3
`
`MYLAN PHARMS. INC. EXHIBIT 1105 PAGE 1
`
`
`
`12/28/2015
`
`Why is Novartis' Copaxone copy lagging? It's all about coverage, analyst explains - FiercePharma
`way he sees it, Sandoz is holding the reins, and as it gradually brings its price
`the ground local expertise. Reserve Your Spot
`Today!
`down, "share will shift," he wrote.
`
`MORE ITEMS
`
`LATEST COMMENTARY
`
`What's the calendar bringing biopharma next year?
`Our top 5 ideas
`The most popular FiercePharma stories of 2015
`Does new scrutiny threaten pharma's specialty
`pharmacy strategy?
`Pfizer responds to FiercePharma
`Jardiance and its CV data? They're no knockout
`punch for stalwart Januvia, Merck says
`
`EVENTS
`
`Data Science for Pharma 2016
`Jan 2628 — London, UK — Sponsored by:
`Hanson Wade
`
`The Pharma CI Europe Conference &
`Exhibition
`February 1819, 2016 — Paris, France
`
`PCC 2016 – CBI’s 13th Pharma Compliance
`Congress
`January 2627, 2016 — Washington, DC
`MORE EVENTS
`
`
`
`There's another question on the minds of industrywatchers, though, and that's
`how Glatopa will affect payer coverage on Teva's nextgen version of Copaxone.
`In July, Gal predicted Glatopa's presence would lead payers to restrict the
`newcomer version as they work to manage costs. And that could be bad news
`for Teva, which managed to convert patients over to the longacting version at a
`rate that had analysts impressed.
`
`Special Report: The top 10 bestselling multiple sclerosis drugs of 2013
`Copaxone Tecfidera | Top 15 drug launch superstars Tecfidera Biogen
`
`Related Articles:
`Novartis off to scorching start with Copaxone generic Glatopa
`Roche's MS hopeful will amp up payer pricing pressure, analyst says
`U.S. court nixes Teva's Copaxone patentagain
`Teva's years of Copaxone brandbuilding pay off in new formula's launch
`What price MS therapy? Thanks to price hikes, $50Kplus, even for decadesold
`meds
`Bad news, TevaSandoz has an FDA nod for generic Copaxone. But when will
`it launch?
`Can Teva persuade payers that pricey longacting Copaxone beats cheap
`generics?
`
`EMAIL ADDRESS
`
`Filed Under Novartis
`
`COMMENTS
`
` SPONSORED
`
`HISTORY IN ORBIT
`50's Classic Adult Pin-Ups. It Was Sexier Than You Thought
`Modeling has changed dramatically since the 50's. Check out what it
`used to be like and the actual girls behind the pin-ups.
`
`Learn More
`
`0 Comments
`
`FiercePharma
`
` Recommend
`
`
`
` Share⤤
`
`Start the discussion…
`
`Be the first to comment.
`
`Subscribe
`
`✉
`
`d
`
`Add Disqus to your site Add Disqus Add
`
`Privacy
`
`
`
` Login
`
`1
`Sort by Best
`
`PRESS RELEASES
`Novartis announces NEJM publication of two major trials showing
`significant efficacy of Cosentyx in ankylosing spondylitis patients
`Aquinnah Pharmaceuticals Receives $5 Million Investment from Takeda
`http://www.fiercepharma.com/story/why-novartis-copaxone-copy-lagging-its-all-about-coverage-analyst-explains/2015-09-11
`
`FEATURED JOBS
`> Need a job? Need to hire? Visit our jobs site.
`
`2/3
`
`MYLAN PHARMS. INC. EXHIBIT 1105 PAGE 2
`
`
`
`Why is Novartis' Copaxone copy lagging? It's all about coverage, analyst explains - FiercePharma
`12/28/2015
`Pharmaceuticals To Advance New Therapies in ALS
`Huya Bioscience International Announces Orphan Drug Designation For
`HBI8000 In Japan
`CSL Behring Submits New Drug Application to Japan';s
`Pharmaceuticals and Medical Devices Agency for rIXFP for Hemophilia
`B Patients
`Porsolt Expands Its in Vitro Drug Discovery Service Capabilities With the
`Acquisition of Fluofarma
`More Press Releases
`
`A publication of
`
`FiercePharma is the pharma
`industry's daily monitor, with
`a special focus on
`pharmaceutical company
`news and the market
`development of FDA
`approved products. Join
`150,000+ pharma industry
`leaders who get
`FiercePharma via daily
`email. Click here to get your
`free weekly email briefing
`today!
`
`The FierceMarkets Network:
`Telecom
`FierceCable
`FierceDeveloper
`FierceWireless:Europe
`FierceWirelessTech
`FierceOnlineVideo
`FierceTelecom
`FierceWireless
`FierceInstaller
`
`Marketing & Retail
`FierceCMO
`FierceMobileMarketer
`FierceRetail
`FierceRetailIT
`FierceMobileRetail
`
`Healthcare
`FierceEMR
`FierceHealthcare
`FierceHealthFinance
`FierceHealthIT
`FierceHealthPayer
`FierceHealthPayerAntiFraud
`FierceMobileHealthcare
`FiercePracticeManagement
`Hospital Impact
`
`Government
`FierceGovernment
`FierceGovernmentIT
`FierceHomelandSecurity
`FierceMobileGovernment
`FierceCities
`FierceGovHealthIT
`
`Life Sciences
`FierceBiotechResearch
`FierceBiotech
`FierceBiotechIT
`FierceCRO
`FierceDrugDelivery
`FierceMedicalDevices
`FiercePharma
`FiercePharmaAsia
`FiercePharmaManufacturing
`FiercePharmaMarketing
`FierceVaccines
`FierceAnimalHealth
`
`Enterprise IT
`FierceBigData
`FierceCIO
`FierceContentManagement
`FierceDevOps
`FierceEnterpriseCommunications
`FierceITSecurity
`FierceMobileIT
`
`Energy
`FierceEnergy
`SmartGridNews
`FierceWater
`
`Finance
`FierceCFO
`FierceFinanceIT
`
`Home Subscribe Manage Newsletter Subscriptions Advertise Contact Mobile Apps RSS Privacy Editors List in Marketplace
`© 2015 FierceMarkets, a division of Questex, LLC. All rights reserved.
`
`http://www.fiercepharma.com/story/why-novartis-copaxone-copy-lagging-its-all-about-coverage-analyst-explains/2015-09-11
`
`3/3
`
`MYLAN PHARMS. INC. EXHIBIT 1105 PAGE 3
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
